PO.CL05.09 · 临床研究

DUOX2在结肠癌中受细胞因子IL-6、IL-22、IL-17A和TNFalpha之间协同作用的精细调控

DUOX2 is finely tuned by synergism between cytokines IL-6, IL-22, IL-17A, and TNFalpha in colon cancer

海报缩略图:DUOX2在结肠癌中受细胞因子IL-6、IL-22、IL-17A和TNFalpha之间协同作用的精细调控
编号 6585 展板 18 时间 4/21 02:00–05:00 区域 Section 45 主讲 Becky Diebold, PhD
分会场 Inflammation, Immunity, and Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Becky A. Diebold1, Agnes Juhasz1, Mariam M. Konaté2, Jiamo Lu1, Guojian Jiang1, Jennifer L. Meitzler1, Yongzhong Wu1, Smitha Antony2, David J. Mallick2, Krishnendu K. Roy2, James H. Doroshow2

1NCI Developmental Therapeutics Branch, Bethesda, MD,2NCI Division of Cancer Treatment and Diagnosis, Bethesda, MD

摘要 Abstract

中文摘要
胃肠道炎症与结直肠癌(CRC)风险增加相关,并与NADPH氧化酶(NOX)亚型NOX1和DUOX2的表达升高相关,二者分别催化超氧阴离子自由基(O2·-)和过氧化氢(H2O2)的合成。为探究调控DUOX2的机制,我们研究了IL-6与IL-17A组合对CRC患者来源细胞(PDC)(T-280R、F725、F1126)与正常结肠细胞系(CCD-112、CCD-841、CCD-18)中DUOX2表达的影响。相较于正常结肠细胞系,CRC PDC中的DUOX2 mRNA水平普遍更高。用IL-6加IL-17A处理PDC 4-6天可导致DUOX2 mRNA和蛋白显著上调。这与显示CRC肿瘤中DUOX2水平较相应非恶性组织升高的数据一致。用IL-6加IL-17A处理HT-29和Ls513结肠癌细胞系8-15天,通过Amplex Red检测测得的DUOX2 mRNA、蛋白及DUOX2依赖性H2O2产量呈现出超过相加效应的增加。对细胞因子处理的HT-29细胞进行RNA-Seq分析表明,STAT3和NFkB信号通路介导了IL-6/IL-17A诱导的DUOX2表达。我们还使用IL-6、IL-17A和TNFalpha的三重细胞因子鸡尾酒研究了DUOX2的调控。在HT29细胞中,加入TNFalpha使DUOX2表达比IL-6加IL-17A处理增加50倍以上,在LS513细胞中增幅更大。DUOX2活性也大幅增加。此外,三重细胞因子处理将mRNA和蛋白表达的时程从数天缩短至24-48小时。当在三重细胞因子处理中以IL-22替代IL-6时,倍数增加更为显著。在这些细胞系中,STAT3通路被IL-6或IL-22激活,NFkB通路被IL-17A和TNFalpha激活。通过siRNA沉默STAT3或RELA几乎完全消除了DUOX2表达。三重细胞因子处理还可在48-72小时内诱导细胞死亡,以及以gamma-H2AX磷酸化为证据的DNA损伤。总之,HT-29和LS513细胞及PDC中的DUOX2表达和DUOX2依赖性H2O2产生可由已知在CRC中过表达的若干促炎细胞因子之间的协同作用进行精细调控。
查看英文原文 English abstract
Gastrointestinal inflammation is associated with an increased risk for colorectal cancer (CRC) and is associated with elevated expression of NADPH oxidase (NOX) isoforms, NOX1 and DUOX2, which catalyze the synthesis of superoxide anion radical (O 2 ·- ) and hydrogen peroxide (H 2 O 2 ), respectively. To explore the mechanisms that regulate DUOX2, we investigated the effects of a combination of IL-6 and IL-17A on DUOX2 expression in CRC patient-derived cells (PDC) (T-280R, F725, F1126) vs. normal colon cell lines (CCD-112, CCD-841, CCD-18). DUOX2 mRNA levels were generally higher across CRC PDCs relative to the normal colon cell lines. Treatment of PDCs with IL-6 plus IL-17A for 4-6 days resulted in significant upregulation of DUOX2 mRNA and protein. This agrees with data demonstrating elevated DUOX2 levels in CRC tumors relative to corresponding non-malignant tissues. Treatment of HT-29 and Ls513 colon cancer cell lines with IL-6 plus IL-17A for 8-15 days yielded greater-than-additive increases in DUOX2 mRNA, protein, and DUOX2-dependent H 2 O 2 production as measured by Amplex Red assays. RNA-Seq analysis of cytokine-treated HT-29 cells indicated that STAT3 and NFkB signaling pathways mediated the IL-6/IL-17A-induced DUOX2 expression. We also investigated the regulation of DUOX2 using a triple-cytokine cocktail of IL-6, IL-17A, and TNFalpha. The inclusion of TNFalpha increased the expression of DUOX2 50-fold more than treatment with IL-6 plus IL-17A in HT29 cells, and even more in LS513 cells. There were also substantial increases in DUOX2 activity. In addition, the triple-cytokine treatment shortened the time course of mRNA and protein expression from several days to 24-48 h. When IL-22 was substituted for IL-6 in the triple-cytokine treatment, the fold-increase was even greater. The STAT3 pathway was activated by IL-6 or IL-22, and the NFkB pathway was activated by IL-17A and TNFalpha in these cell lines. Silencing of STAT3 or RELA by siRNA nearly abolished DUOX2 expression. The triple-cytokine treatments could also induce cell death within 48-72 h, as well as DNA damage as evidenced by phosphorylation of gamma-H2AX. In summary, DUOX2 expression and DUOX2-dependent H 2 O 2 production in HT-29 and LS513 cells and PDCs could be finely tuned by synergism amongst several pro-inflammatory cytokines known to be overexpressed in CRC.
利益披露 Disclosure
B. A. Diebold, None.. A. Juhasz, None.. M. M. Konaté, None.. J. Lu, None.. G. Jiang, None.. J. L. Meitzler, None.. Y. Wu, None.. S. Antony, None.. D. J. Mallick, None.. K. K. Roy, None.. J. H. Doroshow, None.

← 返回 AACR 2026 检索